Literature DB >> 2500459

Lupus anticoagulant, anticardiolipin antibodies, and human immunodeficiency virus in haemophilia.

H Cohen1, I J Mackie, N Anagnostopoulos, G F Savage, S J Machin.   

Abstract

The prevalence of lupus anticoagulant, using the dilute Russell's viper venom time (DRVT), was determined in 22 patients with mild to severe haemophilia A to see if there was any association with the presence of viral disease. Twelve haemophiliacs (58%) were lupus anticoagulant positive, with a mean patient:control ratio of 1.24 (range 1.15-1.52, normal range 0.84-1.06 which partially corrected with lysed, washed platelets). Nine of these patients were IgG or IgM, or both, anticardiolipin antibody positive and nine were human immunodeficiency virus (HIV) antibody positive, but associations between lupus anticoagulant, anticardiolipin antibodies, and HIV antibody positivity were not significant. Mixing studies of normal plasma and immune depleted factor VIII deficient plasma showed that the DRVT ratio increased when the factor VIII concentration fell below 0.15 IU/ml. There was no significant association between plasma factor VIII concentration and positive DRVT results in haemophiliacs. The addition of porcine factor VIII concentrate produced no correction in eight of the 12 with DRVTs indicative of lupus anticoagulant, suggesting that these were prolonged by antiphospholipid activity. It is concluded that the presence of lupus anticoagulant and anticardiolipin antibodies in haemophiliacs may represent an antiphospholipid response to viraemic challenge, not only to HIV but also to other viral antigens, and that a very low factor VIII concentration may produce a false positive DRVT result.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2500459      PMCID: PMC1141992          DOI: 10.1136/jcp.42.6.629

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

1.  Lupus anticoagulant and AIDS.

Authors:  J E Gold; A Haubenstock; R Zalusky
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

2.  Antiphospholipid antibodies in haemophiliacs.

Authors:  W Brien; M Inwood; G Denome
Journal:  Br J Haematol       Date:  1988-02       Impact factor: 6.998

3.  Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity.

Authors:  C B Colaço; D K Male
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

4.  Circulating coagulation inhibitors in the acquired immunodeficiency syndrome.

Authors:  A J Cohen; T M Philips; C M Kessler
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

Review 5.  Blood cell membranes and haemostasis.

Authors:  R F Zwaal; H C Hemker
Journal:  Haemostasis       Date:  1982

6.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

7.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Thyroid autoantigen-induced lymphocyte proliferation in Graves' disease and Hashimoto's thyroiditis.

Authors:  A P Weetman; C Gunn; R Hall; A M McGregor
Journal:  J Clin Lab Immunol       Date:  1985-05

9.  Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity.

Authors:  C B Colaço; G K Scadding; S Lockhart
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

10.  IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis.

Authors:  A K Trull; R Ebringer; G S Panayi; D Colthorpe; D C James; A Ebringer
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

View more
  4 in total

1.  Serum non-organ specific autoantibodies in human immunodeficiency virus 1 infection.

Authors:  F Cassani; L Baffoni; E Raise; L Selleri; M Monti; L Bonazzi; F M Gritti; F B Bianchi
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

2.  Absence of an association between antibodies to retroviral proteins and anticardiolipin antibody and/or lupus anticoagulant in systemic lupus erythematosus.

Authors:  J Matsuda; M Gotoh; K Gohchi; M Tsukamoto; N Saitoh
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

3.  Anti-cardiolipin antibodies and HIV infection.

Authors:  C Maclean; P J Flegg; D C Kilpatrick
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

Review 4.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.